MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

Tenofovir Disoproxil

CAS No. : 201341-05-1

產品活性：Tenofovir Disoproxil (Bis(POC)-PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

研究領域：Anti-infection

作用靶點：HIV  |  Reverse Transcriptase  |  HBV

In Vitro: Tenofovir shows cytotoxic effects on cell viability in HK-2 cells, with IC₅₀ values of 9.21 and 2.77 μM at 48 and 72 h in MTT assay, respectively. Tenofovir diminishes ATP levels in HK-2 cells. Tenofovir (3.0 to 28.8 μM) increases oxidative stress and protein carbonylation in HK-2 cells. Furthermore, Tenofovir induces apoptosis in HK-2 cells, and that apoptosis is induced via mitochondrial damage. Tenofovir and M48U1 formulated in 0.25% HEC each inhibits the replication of both R5-tropic HIV-1_BaL and X4-tropic HIV-1_IIIb in activated PBMCs, and inhibits several laboratory strains and patient-derived HIV-1 isolates. The combined formulation of M48U1 and tenofovir in 0.25% HEC exhibits synergistic antiretroviral activity against infection with R5-tropic HIV-1_BaL, and is not toxic to PBMCs.

In Vivo: Tenofovir Disoproxil Fumarate (20, 50, 140, or 300?mg/kg) administered to BLT mice, shows dose dependent activity during vaginal HIV challenge in BLT humanized mice. Tenofovir Disoproxil Fumarate (50, 140, 300?mg/kg) significantly reduces HIV transmission in BLT mice. Tenofovir Disoproxil Fumarate (0.5, 1.5, or 5.0 mg/kg/day, p.o.) induces a dose-dependent decline in serum viremia in woodchucks chronically infected with WHV. Tenofovir Disoproxil Fumarate administration is safe and effective in the woodchuck model of chronic HBV infection.

相關產品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Oxygen Sensing Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Peldesine dihydrochloride  |  Abacavir sulfate  |  HIV-IN-6  |  Epicoccone B  |  Ditiocarb  |  Nevirapine  |  DAPTA  |  Aloperine  |  Elipovimab  |  HIV-1 inhibitor-52  |  PMEDAP  |  Integracin B  |  FNC-TP  |  DDX3-IN-1  |  Hypericin  |  Sennoside A  |  CK-666  |  Tuvirumab  |  HIV-1 inhibitor-44  |  Flavopiridol  |  Claficapavir  |  Atazanavir  |  1-Deoxymannojirimycin hydrochloride  |  TC14012  |  (Z)-9-Propenyladenine  |  Apabetalone  |  Bicyclol  |  CCR5 antagonist 2  |  2F5 epitope  |  HIV-1 inhibitor-23

熱門產品線：重組蛋白  |  化合物庫  |  天然產物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領；
•   產品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產品，廣泛應用于新藥研發、生命科學等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學分析檢測分析，藥物篩選等專業技術服務；
•   設有專業的實驗中心和嚴格的質控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告，確保產品的高純度、高品質；
•   產品的生物活性多經各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業團隊跟蹤最新的制藥及生命科學研究進展，為您提供*新的活性化合物；
•   與世界各大制藥公司及著名科研機構建立了長期的合作。